Skip to main content

Advertisement

SpringerLink
Log in

Hepatitis B virus infection: An insight into infection outcomes and recent treatment options

  • Review Article
  • Published:
VirusDisease Aims and scope Submit manuscript

Abstract

Hepatitis B virus (HBV) currently infects an estimated population of 2 billion individuals in the world, including 400 million people with chronic HBV infection. HBV virology, replication and the host’s immune response to HBV infection contribute to different infection outcomes. Acute hepatitis HBV infection is self-limiting but it leaves a residual infection that can become active in an individual during immunosuppression. In chronic HBV infection, the virus persistently replicates in hepatocytes leading to immune mediated hepatocellular damage. Despite the inability to remove the virus in more than 70 % of patients, current treatments for chronic HBV infection, interferon alpha and antiviral nucleotide/nucleoside analogues, aim to reduce viral replication to prevent or at least delay the progression to cirrhosis and hepatocellular carcinoma. In both self resolved acute and persistent HBV infection, the long term existence of chromatinised covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes cannot be targeted by current treatments to eliminate these templates to eradicate the viral persistence. Identifying the mechanisms involve in the removal of infected hepatocytes will be useful as treatment options. In this context, DNA based novel therapeutic and immunization strategies might help to remove stable cccDNA and thus viral persistence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005;25(S1):3–8.

    Article  PubMed  Google Scholar 

  2. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci. 2008;15(2):137–45.

    Article  PubMed  Google Scholar 

  3. Ocama P, Opio CK, Lee WM. Hepatitis B virus infection: current status. Am J Med. 2005;118(12):1413.

    Article  PubMed  Google Scholar 

  4. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16):1–31.

    PubMed  Google Scholar 

  5. Osiowy C, Gordon D, Borlang J, Giles E, Villeneuve JP. Hepatitis B virus genotype G epidemiology and co-infection with genotype A in Canada. J Gen Virol. 2008;89(12):3009–15.

    Article  CAS  PubMed  Google Scholar 

  6. Blumberg BS, Alter HJ, Visnich S. A new antigen in leukemia sera. JAMA. 1965;191:541–6.

    Article  CAS  PubMed  Google Scholar 

  7. Blumberg BS. Australia antigen and the biology of hepatitis B. Science. 1977;197(4298):17–25.

    Article  CAS  PubMed  Google Scholar 

  8. Brunello F, Emanuelli G, Camussi G. Markers of type B viral hepatitis. Minerva Med. 1979;70(41):2791–800.

    CAS  PubMed  Google Scholar 

  9. Alberti A, Diana S, Scullard GH, Eddleston WF, Williams R. Full and empty Dane particles in chronic hepatitis B virus infection: relation to hepatitis B e antigen and presence of liver damage. Gastroenterology. 1978;75(5):869–74.

    CAS  PubMed  Google Scholar 

  10. He BG, Melnick JL, Siddiqui A, Robinson WS, Law SW, Lai EC. Molecular cloning and characterization of the cDNA coding for hepatitis B virus surface antigen. Sci Sin [B]. 1985;28(1):49–59.

    CAS  Google Scholar 

  11. Dejean A, Brechot C, Tiollais P, Wain-Hobson S. Characterization of integrated hepatitis B viral DNA cloned from a human hepatoma and the hepatoma-derived cell line PLC/PRF/5. Proc Natl Acad Sci. 1983;80(9):2505–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Kobayashi M, Koike K. Complete nucleotide sequence of hepatitis B virus DNA of subtype adr and its conserved gene organization. Gene. 1984;30(1–3):227–32.

    CAS  PubMed  Google Scholar 

  13. Kramvis A, Kew M, François G. Hepatitis B virus genotypes. Vaccine. 2005;23(19):2409–23.

    Article  CAS  PubMed  Google Scholar 

  14. Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology. 2004;47(6):289–309.

    Article  PubMed  Google Scholar 

  15. Neurath AR, Kent SB, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell. 1986;46(3):429–36.

    Article  CAS  PubMed  Google Scholar 

  16. Glebe D, Urban S. Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol. 2007;13(1):22–38.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Jilbert AR, Mason WS, Kann M. Hepatitis B Virus Replication. In: Locarnini S, Lai C-L, editors. Hepatitis B Virus. London, Atlanta: International Medical Press; 2008. p. 4.1–4.13.

    Google Scholar 

  18. Kim DH, Ni Y, Lee SH, Urban S, Han KH. An anti-viral peptide derived from the pre-S1 surface protein of hepatitis B virus. BMB Rep. 2008;41(9):640–4.

    Article  CAS  PubMed  Google Scholar 

  19. Zoulim F. Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. J Antimicrob Chemother. 2005;55(5):608–11.

    Article  CAS  PubMed  Google Scholar 

  20. Bartenschlager R, Schaller H. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J. 2008;11(9):3413–20.

    Google Scholar 

  21. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, Locarnini S. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 1995;69(6):3350–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  22. Block TM, Guo H, Guo JT. Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis. 2007;11(4):685–706.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Bruss V. Hepatitis B virus morphogenesis. World J Gastroenterol. 2007;13(1):65–73.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Mhamdi M, Funk A, Hohenberg H, Will H, Sirma H. Assembly and budding of a hepatitis B virus is mediated by a novel type of intracellular vesicles. Hepatology. 2007;46(1):95–106.

    Article  CAS  PubMed  Google Scholar 

  25. Funk A, Mhamdi M, Hohenberg H, Heeren J, Reimer R, Lambert C, Prange R, Sirma H. Duck hepatitis B virus requires cholesterol for endosomal escape during virus entry. J Virol. 2008;82(21):10532–42.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Sprengers D, Janssen HL. Immunomodulatory therapy for chronic hepatitis B virus infection in children. Fundam Clin Pharmacol. 2005;19(4):447.

    Article  CAS  PubMed  Google Scholar 

  27. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34(6):1225–41.

    Article  CAS  PubMed  Google Scholar 

  28. Kara IH, Yilmaz ME, Suner A, Kadiroglu AK, Isikoglu B. The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients. Vaccine. 2004;22(29–30):3963–7.

    Article  PubMed  Google Scholar 

  29. Akbar SM, Abe M, Masumoto T, Horiike N, Onji M. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells. J Hepatol. 1999;30(5):755–64.

    Article  CAS  PubMed  Google Scholar 

  30. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999;284(5415):825–9.

    Article  CAS  PubMed  Google Scholar 

  31. Weber F, Kochs G, Haller O. Inverse interference: how viruses fight the interferon system. Viral Immunol. 2004;17(4):498–515.

    Article  CAS  PubMed  Google Scholar 

  32. Scully LJ, Brown D, Lloyd C, Shein R, Thomas HC. Immunological studies before and during interferon therapy in chronic HBV infection: identification of factors predicting response. Hepatology. 1990;12(5):1111–7.

    Article  CAS  PubMed  Google Scholar 

  33. Dandri M, Petersen J. Hepatitis B virus cccDNA clearance: killing for curing? Hepatology. 2005;42(6):1453–5.

    Article  PubMed  Google Scholar 

  34. Rosenthal KL. “Tweaking innate immunity: the promise of innate immunologicals as anti-infectives. Can J Infect Dis Med Microbiol. 2006;17(5):307–14.

    PubMed Central  PubMed  Google Scholar 

  35. Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, Rodgers S, Kurtovic J, Chang J, Lewin S, Desmond P, Locarnini S. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology. 2007;45(1):102–10.

    Article  CAS  PubMed  Google Scholar 

  36. Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007;20(3):426–39.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Rehermann B. Intrahepatic T cells in hepatitis B: viral control versus liver cell injury. J Exp Med. 2000;191(8):1263–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.

    Article  PubMed  Google Scholar 

  39. Yuen MF, Lai CL. In: Locarnini S, Lai CL, editors. The natural history of chronic hepatitis B, vol. 1. London, Atlanta: International Medical Press; 2008. p. 12.1–12.11.

    Google Scholar 

  40. Villeneuve JP. The natural history of chronic hepatitis B virus infection. J Clin Virol. 2005;34(1):S139–42.

    Article  CAS  PubMed  Google Scholar 

  41. Dai CY, Chuang WL, Huang JF, Yu ML. Hepatitis B e antigen-negative patients with persistently normal alanine aminotransferase levels and hepatitis B virus DNA >2000 IU/mL. Hepatology. 2009;49(2):705–6.

    Article  Google Scholar 

  42. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther. 2004;20(10):1053–62.

    Article  CAS  PubMed  Google Scholar 

  43. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology. 2004;40(4):874–82.

    Article  CAS  PubMed  Google Scholar 

  44. Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B). Hepatology. 1981;1(5):377–85.

    Article  PubMed  Google Scholar 

  45. Zuckerman J. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ. 1997;314(7077):329–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. McMahon BJ. Antibody levels and protection after hepatitis B vaccine: results of a 22- year follow-up study and response to a booster dose. J Infect Dis. 2009;200:1390–6.

    Article  CAS  PubMed  Google Scholar 

  47. Chathuranga LS, Noordeen F, Abeykoon AM. Immune response to hepatitis B vaccine in a group of health care workers in Sri Lanka. Int J Infect Dis. 2013;17(11):e1078–9.

    Article  CAS  PubMed  Google Scholar 

  48. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. CID. 2011;53:68–75.

    Article  Google Scholar 

  49. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis. 2003;23(1):81–8.

    Article  CAS  PubMed  Google Scholar 

  50. Younger HM, Bathgate AJ, Hayes PC. Review article: nucleoside analogues for the treatment of chronic hepatitis B. Aliment Pharmacol Ther. 2004;20(11–12):1211–30.

    Article  CAS  PubMed  Google Scholar 

  51. Fournier C, Zoulim F. Combination therapy in chronic hepatitis B. Gastroenterol Clin Biol. 2008;32(1 Pt 2):S42–9.

    Article  CAS  PubMed  Google Scholar 

  52. Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat. 2005;12(4):333–45.

    Article  CAS  PubMed  Google Scholar 

  53. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007;45(2):307–13.

    Article  CAS  PubMed  Google Scholar 

  54. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49(4):1151–7.

    Article  CAS  PubMed  Google Scholar 

  55. Locarnini S, Bathholomeusz A. Emergence and patterns of drug resistance, vol. 1. London, Atlanta: International Medical Press; 2008. p. 12.1–12.11.

    Google Scholar 

  56. Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat. 2002;9(6):393–9.

    Article  PubMed  Google Scholar 

  57. Zoulim F. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother. 2004;15(6):299–305.

    Article  CAS  PubMed  Google Scholar 

  58. Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro. Antimicrob Agents Chemother. 2013;57(11):5291–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  59. Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 2013;57(11):5299–306.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Al-Mahtab M, Bazinet M, Vaillant A. Preliminary evidence of rapid HBsAg seroconversion in patients with chronic hepatitis B (CHB) treated with a DNA-based amphipathic polymer. Antivir Res. 2010;86(1):A28.

    Article  Google Scholar 

  61. Al-Mahtab M, Bazinet M, Vaillant A. REP 9AC is a potent HBsAg release inhibitor which clears serum HBSAg and elicits SVR in patients with chronic hepatitis B. J Hepatol. 2011;54(1):S34.

    Article  Google Scholar 

  62. Noordeen F. Development of antiviral therapies for chronic hepatitis B virus infection. Digital research theses collection of University of Adelaide, 09PH N818. 2010. http://library.adelaide.edu.au/item/1523542.

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka

    Faseeha Noordeen

Authors
  1. Faseeha Noordeen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faseeha Noordeen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Noordeen, F. Hepatitis B virus infection: An insight into infection outcomes and recent treatment options. VirusDis. 26, 1–8 (2015). https://doi.org/10.1007/s13337-015-0247-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13337-015-0247-y

Keywords

Search

Navigation